| pubmed-article:6540580 | pubmed:abstractText | Some Ca2+-antagonists are used for the treatment of angina pectoris. In the present study niludipine (Bay a 7168) was assessed in various types of angina pectoris cases. Niludipine, a Ca2+-antagonist of the dihydropyridine derivatives, was administered to 50 patients, 27 with effort angina pectoris, 4 with rest angina, 7 with effort plus rest angina, 4 with variant angina, 8 with angina following myocardial infarction in the doses of 60 mg/day or 120 mg/day for 4 weeks and the changes of subjective symptoms and objective findings were evaluated. Improvement was found by 69.6% for effort angina, by 75% (3/4) for rest angina, and side effects by 6% but mild degree--no facial flash, headache, hypotension were observed. The results suggest that niludipine is a safe antianginal Ca2+-antagonist with broad effectiveness for various types of angina pectoris. | lld:pubmed |
